PharmaJet Partner Technovalia Announces Interim Results of Needle-free COVID-19 Vaccine Trial
- Category: Vaccines
- Published on Wednesday, 16 February 2022 11:35
- Hits: 2676
Needle-free DNA based COVID vaccine tested in Australia yields no safety concerns
GOLDEN, CO, USA I February 15, 2022 IPharmaJet®, a biotech company that has developed a more effective way of administering drugs and biologics with their innovative, needle-free injection technology, announced that their partner, Technovalia, has reported interim safety results from their needle-free SARS-CoV2 DNA vaccine phase 1 trial. Interim safety data of COVIGEN, their DNA COVID-19 vaccine candidate, is well tolerated and no safety concerns were observed.
The purpose of the phase 1 trial was to assess the safety and immunogenicity of two COVIGEN doses given one month apart to healthy volunteers aged 18 to 75 years of age who had not yet received a COVID-19 vaccination. Mr. Laurent Dapremont, Chief Executive Officer of Technovalia said, “We are pleased with these positive interim safety results from the ongoing COVALIA study which reinforce the existing pre-clinical data available. COVIGEN is the first plasmid-DNA vaccine to be tested in Australia and it is encouraging to observe no safety concern in the participants. We believe both mRNA and DNA vaccines will play an important role to combat the spread of COVID.” A study group will also assess COVIGEN as a booster dose on healthy subjects fully vaccinated.
Chris Cappello, President and CEO, PharmaJet commented, “We welcome this positive news and are proud to be part of the COVIGEN vaccine development with Technovalia, BioNet, and their Australian partners. These results are consistent with data from other DNA and RNA based vaccines administered using the PharmaJet Needle-free Injection Systems (NFIS). The PharmaJet NFIS is being used as the method of delivery on 20+ COVID vaccine development programs including the world’s first plasmid-based DNA vaccine recently receiving Emergency Use Authorization for COVID in India.”
For more information about PharmaJet visit www.pharmajet.com.
Refer to Instructions for Use to ensure safe injections and to review risks.
PharmaJet’s mission is to improve people’s lives through needle-free technology. PharmaJet Needle-free Systems provide increased vaccine effectiveness, a preferred patient and caregiver experience, and a proven path to commercialization. They are also safe, fast, and easy-to-use. The Stratis® System has U.S. FDA 510(k) marketing clearance, CE Mark, and WHO PQS certification to deliver medications and vaccines either intramuscularly or subcutaneously. The Tropis® System has CE Mark and WHO PQS certification for intradermal injections. For more information visit www.pharmajet.com. Follow us on LinkedIn.
Melbourne-based Technovalia is a privately-owned Australian biotech company dedicated to the research and development of innovative vaccines and diagnostics. In partnership with several academic organizations and international companies, Technovalia is investing in the development of new technology platforms that have the potential to significantly improve protection against several infectious diseases by producing safer, more stable and more cost-effective vaccines and diagnostics. Technovalia is working with The Telethon Kids Institute, WA, to test BioNet’s recombinant acellular pertussis-only vaccine Pertagen® in PertaPrime, a phase II-III randomised controlled trial in Australia. www.technovalia.com
BioNet is a French-Thai biotech company focusing on the discovery, manufacturing and supply of innovative life-saving vaccines. BioNet is the world’s only manufacturer of recombinant pertussis-only vaccine (Pertagen®, aP vaccine) and a recombinant TdaP vaccine (Boostagen®), containing a genetically inactivated pertussis toxin (PTgen). BioNet has been developing genetic vaccines against SARS-CoV2 and its variant strains using DNA and mRNA technology platforms. COVIGEN is a COVID-19 DNA vaccine being evaluated in human trials in Australia. www.bionet-asia.com